Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
14 November 2013Website:
http://www.tandemdiabetes.comNext earnings report:
01 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 32 min agoDividend
Analysts recommendations
Institutional Ownership
TNDM Latest News
Flat revenue growth might be in store for the company in a very crucial market.
By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes Care is enhancing the pump's functionality.
Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for people living with the condition.
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Lilly's Lyumjev in the European Union.
Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.
The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy.
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) today announced the planned release of version 2.8.2 of its Apple iOS t:connect mobile app in the United States on August 20, 2024 to correct an issue described in a March 2024 recall that can cause rapid depletion of a user's t:slim X2 insulin pump battery. This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to see following the release of version 2.7.1 of the.
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #TandemMobi--Tandem Diabetes Care today presented positive real-world data from a Tandem Mobi user satisfaction survey at the 2024 ADA Scientific Sessions.
Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM).
What type of business is Tandem Diabetes Care?
Tandem Diabetes Care, Inc. is a company that designs, manufactures, and commercializes medical devices for insulin therapy. Founded in 2006, the company is headquartered and has manufacturing facilities in San Diego, California. The company's activities are fully focused on the flagship pump platform - the t:slim X2 insulin delivery system and additional product offerings. The t:slim X2 hardware platform is the only commercial insulin pump that allows users to quickly and easily update their pump software from a personal computer. In addition to Tandem insulin pumps, the company sells disposable products or consumables - insulin storage and delivery cartridges and infusion sets.
What sector is Tandem Diabetes Care in?
Tandem Diabetes Care is in the Healthcare sector
What industry is Tandem Diabetes Care in?
Tandem Diabetes Care is in the Medical Devices industry
What country is Tandem Diabetes Care from?
Tandem Diabetes Care is headquartered in United States
When did Tandem Diabetes Care go public?
Tandem Diabetes Care initial public offering (IPO) was on 14 November 2013
What is Tandem Diabetes Care website?
https://www.tandemdiabetes.com
Is Tandem Diabetes Care in the S&P 500?
No, Tandem Diabetes Care is not included in the S&P 500 index
Is Tandem Diabetes Care in the NASDAQ 100?
No, Tandem Diabetes Care is not included in the NASDAQ 100 index
Is Tandem Diabetes Care in the Dow Jones?
No, Tandem Diabetes Care is not included in the Dow Jones index
When was Tandem Diabetes Care the previous earnings report?
No data
When does Tandem Diabetes Care earnings report?
The next expected earnings date for Tandem Diabetes Care is 01 November 2024